John T. Carpenter

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Marc L. Citron, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2003 · 1.6K citations

Medicine, Oncology, Pharmacology +15

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

Robert B. Diasio, T L Beavers, John T. Carpenter · Journal of Clinical Investigation · 1988 · 500 citations · Full text

Medicine, Biochemistry, Pharmacology +14

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

Laura J. Esserman, Donald A. Berry, Angela DeMichele et al. · Journal of Clinical Oncology · 2012 · 441 citations · Full text

Medicine, Biostatistics, Oncology +11

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Laura J. Esserman, Donald A. Berry, Maggie C.U. Cheang et al. · Breast Cancer Research and Treatment · 2011 · 376 citations · Full text

Medicine, Biostatistics, Oncology +17